X
CAD
$1000,395,000
CannTrust
BOUGHT DEAL, JUNE 2018
TRANSACTIONS
OUR TRANSACTIONS HELP IDENTIFY, FOSTER AND CREATE INVESTMENT OPPORTUNITIES IN THE HEALTHCARE SECTOR, ON BEHALF OF COMPANIES AND INVESTORS
FILTER BY
>
Service
>
Sector
>
Stage
>
X
US $48,990,000
ESSA Pharma Inc.
PUBLIC OFFERING
JULY 2020
HOUSTON and VANCOUVER, BC, July 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritten public offering of 7,100,000 common shares of the Company at a public offering price of US$6.00 per share, before underwriting discounts, for an aggregate offering of approximately US$42.6 million (the "Offering"). ESSA granted the underwriters a 30-day option to purchase up to an additional 1,065,000 common shares (the "Option"), and the underwriters exercised the Option on July 29, 2020. The proceeds to ESSA from the Offering, including the exercise of the Option, were approximately US$45.0 million after deducting underwriting discounts and commissions (such commission being equal to 6% of the aggregate gross proceeds of the Offering) and other estimated offering expenses. Existing investors participated in the financing along with new investors Pfizer Inc. (NYSE: PFE), Avidity Partners, CAM Capital, Point72, Ridgeback Capital, Sphera Healthcare and Vivo Capital.
X
CAD $28,750,000
Antibe Therapeutics Inc.
BOUGHT DEAL
JUNE 2020
Toronto, Ontario--(Newsfile Corp. - June 30, 2020) - Antibe Therapeutics Inc. (TSXV: ATE) ("Antibe" or the "Company") announced that it closed its previously announced bought deal public offering of 62,500,000 units of the Company (the "Units") at a price of $0.40 per Unit (the "Offering Price") plus the exercise in full of the Underwriters' over-allotment option of 9,375,000 units for aggregate gross proceeds of $28,750,000 (the "Offering"). The Offering was made pursuant to an underwriting agreement dated June 15, 2020 with a syndicate of underwriters led by Bloom Burton Securities Inc., together with Echelon Wealth Partners Inc., Paradigm Capital Inc., Raymond James Ltd., Stifel GMP and Industrial Alliance Securities Inc. (collectively, the "Underwriters").
X
CAD $15,525,000
Appili Therapeutics Inc.
PUBLIC OFFERING
JUNE 2020
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”) announced the closing of its previously announced public offering (the “Public Offering”) of units (the “Units”). The Public Offering was made pursuant to an agency agreement entered into with a syndicate of agents led by Bloom Burton Securities Inc. (the “Lead Agent”) and including Mackie Research Capital Corporation, Industrial Alliance Securities Inc., Haywood Securities Inc., and Richardson GMP Limited (collectively with the Lead Agent, the “Agents”) and the Company.
X
CAD $15,000,000
Greenbrook TMS
PUBLIC OFFERING
MAY 2020
TORONTO, ON, May 21, 2020 – Greenbrook TMS Inc. (“Greenbrook” or the “Company”) (TSX: GTMS) is pleased to announce the closing of its previously announced public offering (the “Offering”) of common shares of the Company (the “Offered Shares”). The Offering was made pursuant to an agency agreement (the “Agency Agreement”) entered into among Bloom Burton Securities Inc. and Clarus Securities Inc., as co-lead agents, Canaccord Genuity Corp., Desjardins Securities Inc. and Stifel GMP (collectively, the “Agents”).
X
CAD $56,000,000
adMare BioInnovations
MERGER & ACQUISTION ADVISORY
MARCH 2020
X
CAD $40,250,000
Medicenna Therapeutics Corp.
PUBLIC OFFERING
MARCH 2020
X
CAD $10,250,000
Appili Therapeutics Inc.
PUBLIC OFFERING
FEBRUARY 2020
X
Aurinia Pharmaceuticals
MONETIZATION PLANNING
JANUARY 2020
X
US $116,955,000
Trillium Therapeutics Inc.
Public Offering
JANUARY 2020
X
US $ 60,000,000
Xenon Pharmaceuticals Inc.
Public Offering
JANUARY 2020
X
Neoleukin Therapeutics
MONETIZATION PLANNING
DECEMBER 2019
X
US $191,700,000
Aurinia Pharmaceuticals
PUBLIC OFFERING
DECEMBER 2019
X
CAD $3,000,000
Klinik Health Ventures Corp.
IPO
DECEMBER 2019
X
CAD $18,000,000
BEACON™
SERIES A FOLLOW-ON
NOVEMBER 2019
X
CAD $6,900,000
Medicenna Therapeutics Corp.
PUBLIC OFFERING
OCTOBER 2019
X
US $79,374,102
Bellus Health
U.S. IPO
SEPTEMBER 2019
X
US $36,000,000
ESSA Pharma Inc.
PUBLIC OFFERING; PRIVATE PLACEMENT
AUGUST 2019
X
US $35,000,000
Titan Medical Inc.
COMMON SHARE PURCHASE AGREEMENT
AUGUST 2019
X
CAD $8,050,000
Antibe Therapeutics Inc.
PUBLIC OFFERING
AUGUST 2019
X
CAD $15,200,000
Resverlogix Corp.
EQUITY OFFERING
JUNE 2019
X
CAD $50,025,008
HLS Therapeutics Inc.
BOUGHT DEAL
JUNE 2019
X
CAD $30,579,250
Greenbrook TMS
BOUGHT DEAL; PRIVATE PLACEMENT
MAY 2019
X
CAD $5,260,000
Avivagen
PRIVATE PLACEMENT
MARCH 2019
X
US $28,750,000
Titan Medical Inc.
PUBLIC OFFERING
MARCH 2019
X
CAD $3,586,813
Appili Therapeutics Inc.
PRIVATE PLACEMENT
MARCH 2019
X
Aurinia Pharmaceuticals
MONETIZATION PLANNING
FEBRUARY 2019
X
US $110,000,000
Nuvo Pharmaceuticals Inc.
MERGER & ACQUISTION ADVISORY
DECEMBER 2018
X
CAD $4,000,000
Medicenna Therapeutics Corp.
Public Offering
DECEMBER 2018
X
CAD $35,000,000
Bellus Health
EQUITY OFFERING
DECEMBER 2018
X
Aurinia Pharmaceuticals
MONETIZATION PLANNING
OCTOBER 2018
X
UP TO CAD $88,000,000
Pediapharm Inc.
Merger & Acquisition Advisory
OCTOBER 2018
X
US $ 63,000,000
Xenon Pharmaceuticals Inc.
Public Offering
SEPTEMBER 2018
X
CAD $9,150,000
LED Medical Diagnostics Inc.
Private Placement
SEPTEMBER 2018
X
CAD $10,000,000
Hamilton Thorne Ltd.
BOUGHT DEAL; PRIVATE PLACEMENT
AUGUST 2018
X
US $19,198,935
Titan Medical Inc.
PUBLIC OFFERING
AUGUST 2018
X
CAD $16,000,000
Mimi's Rock
DEBT FINANCING
JULY 2018
X
CAD $17,400,000
Mimi's Rock
PRIVATE PLACEMENT
JULY 2018
X
U.S. R&D Institute
MONETIZATION PLANNING
JUNE 2018
X
US $20,000,000
Greenbrook TMS
PRIVATE PLACEMENT
JUNE 2018
X
Multinational Pharmaceutical Company
MONETIZATION PLANNING
MAY 2018
X
Multinational Pharmaceutical Company
MONETIZATION PLANNING
MAY 2018
X
CAD $6,184,647
Kneat Software
PRIVATE PLACEMENT
APRIL 2018
X
CAD $10,139,988
Titan Medical Inc.
PUBLIC OFFERING
APRIL 2018
X
CAD $27,797,275
Sunniva Inc.
BOUGHT DEAL; PUBLIC OFFERING
MARCH 2018
X
CAD $14,375,000
Immunovaccine Inc.
BOUGHT DEAL
FEBRUARY 2018
X
Satellos Bioscience Inc.
Company Creation
2018
Satellos is a private, Canadian-based regenerative medicine company formed in 2018. The initial focus of the company is muscle regeneration, with a lead program in Duchenne Muscular Dystrophy.
X
US $26,040,000
ESSA Pharma Inc.
PUBLIC OFFERING
JANUARY 2018
X
Precision Nutrition
MERGER & ACQUISTION ADVISORY
DECEMBER 2017
X
CAD $20,000,000
Bellus Health
PUBLIC EQUITY OFFERING
DECEMBER 2017
X
CAD $23,000,000
Titan Medical Inc.
PUBLIC OFFERING
DECEMBER 2017
X
CAD $4,000,000
Avivagen
PRIVATE PLACEMENT
NOVEMBER 2017
X
CAD $8,925,000
Titan Medical Inc.
PUBLIC OFFERING
JUNE 2017
X
CAD $4,983,000
Antibe Therapeutics Inc.
PUBLIC OFFERING
JUNE 2017
X
CAD $10,000,000
Resverlogix Corp.
PUBLIC OFFERING
JUNE 2017
X
TechAlliance of Southwestern Ontario
MONETIZATION PLANNING
APRIL 2017
X
EUR €13,900,000
Hamilton Thorne Ltd.
MERGER & ACQUISTION ADVISORY
APRIL 2017
X
CAD $12,500,000
Hamilton Thorne Ltd.
PRIVATE PLACEMENT
APRIL 2017
X
Weed MD
MONETIZATION PLANNING
MAY 2017
X
Alberta Innovates
MONETIZATION PLANNING
MAY 2017
X
NeuPath Health
Company Creation
2017
NeuPath is Canada's largest provider of chronic pain services. Through their network and brands, NeuPath is constantly expanding the scope of their services to serve communities.
X
CAD $7,500,000
Titan Medical Inc.
PUBLIC OFFERING
MARCH 2017
X
Alberta Innovates
MONETIZATION PLANNING
MARCH 2017
X
Aquinox Pharmaceuticals Inc.
MONETIZATION PLANNING
MARCH 2017
X
CAD $4,000,000
Medicenna Therapeutics Corp.
Private Placement
March 2017
X
CAD $14,400,000
LED Medical Diagnostics Inc.
Private Placement
February 2017
X
US $10,250,000
LED Medical Diagnostics Inc.
MERGER & ACQUISITION ADVISORY
FEBRUARY 2017
X
CAD $100,050,000
Knight Therapeutics Inc.
Bought Deal
December 2016
X
CAD $10,000,000
Medicenna Therapeutics Corp.
Private Placement
December 2016
X
CAD $5,004,000
CannaRoyalty Corp.
Private Placement
OCTOBER 2016
X
CAD $10,000,000
Newtopia Inc.
Series A Financing
OCTOBER 2016
X
CAD $11,428,000
Titan Medical Inc.
Public Offering
OCTOBER 2016
X
CAD $6,000,000
Red Leaf Medical Inc.
MERGER & ACQUISITION ADVISORY
SEPTEMBER 2016
X
Bellus Health Inc.
MONETIZATION PLANNING
SEPTEMBER 2016
X
Clementia Pharmaceuticals
MONETIZATION PLANNING
SEPTEMBER 2016
X
Response Biomedical Corp.
MERGER & ACQUISITION ADVISORY
AUGUST 2016
X
US $107,000,000
Noden Pharma Inc.
Private Placement
JULY 2016
X
Noden Pharma Inc.
MERGER & ACQUISITION ADVISORY
JULY 2016
X
Medicago Inc.
MONETIZATION PLANNING
JULY 2016
X
CAD $230,000,000
Knight Therapeutics Inc
Bought Deal
JUNE 2016
X
CAD $15,000,000
Titan Medical Inc.
Public Offering
APRIL 2016
X
Canadian Public Pharmaceutical Company
Valuation Opinion
MARCH 2016
X
CAD $82,980,000
Nuvo Reserach Inc.
Fairness Opinion
MARCH 2016
X
CAD $12,080,000
Titan Medical Inc.
Private Offering
FEBRUARY 2016
X
Medicenna Therapeutics Corp.
MONETIZATION PLANNING
FEBRUARY 2016
X
US $148,000,000
Tribute Pharmaceuticals Canada Inc.
Merger & Acquisition Advisory
FEBRUARY 2016
X
Canadian Public Biotech Company
MERGER & ACQUISITION ADVISORY
JANUARY 2016
X
CAD $12,300,000
INTEGA Skin Sciences Inc.
Debt
JANUARY 2016
X
US $15,000,000
ESSA Pharma Inc.
Private Placement
JANUARY 2016
X
Appili Therapeutics Inc.
Company Creation
2015
Appili Therapeutics Inc. was founded to advance the global fight against infectious disease by matching clearly defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors, and society face in this critical disease space.
X
Grey Wolf Animal Health Inc.
Company Creation
2015
Grey Wolf Animal Health is a specialty animal health company focused on improving the lives and well-being of vets and pets in Canada and abroad. Founded in 2015 by Dr. Ian Sandler, their mission is to identify and bring to market products, solutions and services that meet the underserved needs of vets, pets and clinics across Canada.
X
Triumvira Immunologics Inc.
Company Creation
2015
Triumvira is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
X
Medicago Inc.
Monetization Planning
NOVEMBER 2015
X
CAD $2,120,000
LED Medical Diagnostics Inc.
Public Offering
NOVEMBER 2015
X
CAD $47,000,000
Alveda Pharmaceuticals Inc.
Merger & Acquisition Advisory
NOVEMBER 2015
X
Arthritis Innovation Corporation
Valuation Opinion
October 2015
X
US $200,000,000
HLS Therapeutics Inc.
Private Placement
AUGUST 2015
X
US $185,000,000
HLS Therapeutics Inc.
Syndicated Loan
AUGUST 2015
X
Exerkine Corporation
Merger & Aquisition Advisory
AUGUST 2015
X
CAD $1,590,000
Diagnos Inc.
Private Placement
JULY 2015
X
CAD $2,680,000
Agility Health Inc.
Public Offering
JUNE 2015
X
CAD $4,020,000
Medicure Inc.
Bought Deal; Private Placement
JUNE 2015
X
CAD $12,500,000
Tribute Pharmaceuticals Canada Inc.
Private Placement
JUNE 2015
X
CAD $25,000,000
Medical Futures Inc.
Merger & Acquisition Advisory
JUNE 2015
X
CAD $12,000,000
Tribute Pharmaceuticals Canada Inc.
Raising Capital & Financing
MAY 2016
X
US $55,150,000
Trillium Therapeutics Inc.
Public Offering
APRIL 2015
X
CAD $24,010,000
Profound Medical Corp.
Private Placement
APRIL 2015
X
CAD $5,500,000
Pediapharm Inc.
Private Placement
MARCH 2015
X
CAD $27,370,000
CRH Medical Corporation
Bought Deal
MARCH 2015
X
Qing Bile Therapeutics Inc.
Company Creation
2015
Qing Bile Therapeutics is a preclinical stage, private Canadian biotechnology company founded in 2015 based on research from Dr. Victor Ling’s laboratory at the University of British Columbia and BC Cancer Agency. Qing Bile has identified tetrahydroxylated bile acids (THBAs) to treat cholestatic and metabolic diseases with high unmet need.
X
Ontario Academic Institution
Monetization Planning
JANUARY 2015
X
Xenon Pharmaceuticals Inc.
Monetization Planning
JANUARY 2015
X
US $12,000,000
ESSA Pharma Inc.
Private Placement
JANUARY 2015
X
Pharmascience Inc.
Monetization Planning
JANUARY 2015
X
CAD $100,000,000
Knight Therapeutics Inc.
Bought Deal
DECEMBER 2014
X
US $52,000,000
CRH Medical Corporation
Debt
DECEMBER 2014
X
US $73,200,000
CRH Medical Corporation
Merger & Acquisition Advisory
DECEMBER 2014
X
CAD $1,350,000
Essa Pharma Inc.
Private Placement
OCTOBER 2014
X
US $45,000,000
Nuvo Research Inc.
Merger & Acquisition Advisory
OCTOBER 2014
X
iCo Therapeutics Inc.
Monetization Planning
OCTOBER 2014
X
TEC Edmonton
Monetization Planning
OCTOBER 2014
X
CAD $5,766,100
Bioniche Life Sciences Inc.
Private Placement
SEPTEMBER 2014
X
CAD $3,400,000
Essa Pharma Inc.
Private Placement
JULY 2014
X
CAD $30,026,500
Tribute Pharmaceuticals Inc.
Public Offering
JULY 2014
X
Warnex Inc.
MERGER & ACQUISITION ADVISORY
MAY 2014
X
Plantform Corporation
MONETIZATION PLANNING
MAY 2014
X
McMaster University Faculty of Health Sciences
MONETIZATION PLANNING
MAY 2014
X
CAD $180,075,000
Knight Therapeutics Inc.
Private Placement
APRIL 2014
X
CAD $3,400,000
Agility Health Inc.
Private Placement
APRIL 2014
X
Antibe Therapeutics Inc.
MONETIZATION PLANNING
APRIL 2014
X
CAD $3,130,000
Nuvo Research Inc.
Private Placement
APRIL 2014
X
Pediapharm Inc.
Monetization Planning
APRIL 2014
X
CPDC
Monetization Planning
MARCH 2014
X
CAD $3,020,000
Antibe Therapeutics Inc.
Raising Capital & Financing
MARCH 2013
X
CAD $3,100,000
Nuvo Pharmaceuticals Inc.
Private Placement
MARCH 2014
X
CAD $3,000,000
Antibe Therapeutics Inc.
Private Placement
MARCH 2014
X
Bioniche Life Sciences Inc.
MERGER & ACQUISITION ADVISORY
MARCH 2014
X
Trillium Therapeutics Inc.
MONETIZATION PLANNING
MARCH 2014
X
Xenon Pharmaceuticals Inc.
Monetization Planning
FEBRUARY 2014
X
CAD $7,530,000
Triton Pharma Inc.
Mergers & Acquisition Advisory
JANUARY 2014
X
CAD $33,000,000
Stem Cell Therapeutics Corp.
Private Placement
DECEMBER 2013
X
Sirona Biochem Corp.
MONETIZATION PLANNING
OCTOBER 2013
X
Approx. CAD $17,000,000
STI Technologies Ltd.
Private Equity Investment
SEPTEMBER 2013
X
CAD $9,804,500
Bioniche Life Sciences Inc.
Public Offering
SEPTEMBER 2013
X
Up to CAD $4,000,000
Response Biomedical Corp.
Private Placement
SEPTEMBER 2013
X
Approx. CAD $357,000,000
Medicago Inc.
MERGER & ACQUISITION ADVISORY
SEPTEMBER 2013
X
CIMTEC
MONETIZATION PLANNING
SEPTEMBER 2013
X
Aquinox Pharmaceuticals Inc.
MONETIZATION PLANNING
SEPTEMBER 2013
X
US $6,000,000
Tribute Pharmaceuticals Inc.
Debt
August 2013
X
Approx. CAD $13,000,000
Thallion Pharmaceuticals Inc.
MERGER & ACQUISITION ADVISORY
August 2013
X
CAD $3,155,100
Antibe Therapeutics Inc.
Initial Public Offering
JUNE 2013
X
CAD $3,379,520
iCo Therapeutics Inc.
Overnight Offering
MAY 2013
X
CAD $40,000,000
Trimel Pharmaceuticals Corp.
Public Offering
APRIL 2013
X
CAD $3,100,000
Stem Cell Therapeutics Corp.
Public Offering
MARCH 2013
X
Victhom Human Bionics Inc.
MERGER & ACQUISITION ADVISORY
MARCH 2013
X
Tekmira Pharmaceuticals
MONETIZATION PLANNING
JANUARY 2013
X
CRH Medical Corp.
MONETIZATION PLANNING
JANUARY 2013
X
CAD $12,500,000
Agility Health Inc.
Private Placement
DECEMBER 2012
X
Approx. US 510,000,000
YM BioSciences Inc.
MERGER & ACQUISITION ADVISORY
DECEMBER 2012
X
Ontario Institute for Cancer Research
MONETIZATION PLANNING
DECEMBER 2012
X
Warnex Inc.
MERGER & ACQUISITION ADVISORY
OCTOBER 2012
X
CML Healthcare Inc.
MONETIZATION PLANNING
OCTOBER 2012
X
US $7,500,000
Trimel Pharmaceuticals Corp.
Venture debt
JULY 2012
X
CAD $2,550,000
iCo Therapeutics Inc.
Overnight Offering
JULY 2012
X
Pharmagap Inc.
MERGER & ACQUISITION ADVISORY
JULY 2012
X
Bellus Health Inc.
MONETIZATION PLANNING
JUNE 2012
X
Sirona Biochem Corp.
MONETIZATION PLANNING
JUNE 2012
X
Canadian Public Biotechnology Company
MONETIZATION PLANNING
JUNE 2012
X
CAD $8,000,000
Nuvo Pharmaceuticals Inc.
Secured Debt
MAY 2012
X
US $6,000,000
Stellar Pharmaceuticals Inc.
Secured Debt
MAY 2012
X
Patient Home Monitoring Corp.
MONETIZATION PLANNING
APRIL 2012
X
Antibe Therapeutics Inc.
MONETIZATION PLANNING
JANUARY 2012
X
CAD $448,231
Microbix Biosystems Inc.
Public Offering
DECEMBER 2011
X
Approx. CAD $10,000,000
Stellar Pharmaceuticals Inc.
MERGER & ACQUISITION ADVISORY
DECEMBER 2011
X
CAD $3,520,000
Botaneco Inc.
Private Placement
OCTOBER 2011
X
CAD $10,000,000
Allon Therapeutics Inc.
Public Offering
OCTOBER 2011
X
Advitech Inc.
MERGER & ACQUISITION ADVISORY
OCTOBER 2011
X
CAD $25,000,000
Medicago Inc.
Private Placement
SEPTEMBER 2011
X
CAD $2,200,000
Lorus Therapeutics Inc.
Public Offering
AUGUST 2011
X
CAD $12,600,000
Resverlogix Corp.
Overnight Offering
JUNE 2011
X
Nuvo Pharmaceuticals Inc.
MONETIZATION PLANNING
JUNE 2011
X
CAD $717,500
Microbix Biosystems Inc.
Private Placement
APRIL 2011
X
Miraculins Inc.
MONETIZATION PLANNING
APRIL 2011
X
CAD $17,399,976
Medicago Inc.
Overnight Offering
MARCH 2011
X
CAD $2,000,000
Stem Cell Therapeutics Corp.
Overnight Offering
MARCH 2011
X
CAD $40,250,000
Paladin Labs Inc.
Bought Deal
FEBRUARY 2011
X
CAD $1,808,866
Ventripoint Inc.
Private Placement
JANUARY 2011
X
CAD $46,000,000
YM Biosciences Inc.
Public Offering
DECEMBER 2010
X
CAD$ 5,000,000
Agility Health Inc.
Term Debt Financing
DECEMBER 2010
X
CAD $28,777,600
Oncolytics Biotech Inc.
Bought Deal
OCTOBER 2010
X
CAD $7,465,100
ImmunoVaccine Inc.
Public Offering
SEPTEMBER 2010
X
CAD $7,500,000
Medicago Inc.
Overnight Offering
AUGUST 2010
X
Miraculins Inc.
MERGER & ACQUISITION ADVISORY
AUGUST 2010
X
CAD $10,000,000
Resverlogix Corp.
Overnight Offering
JUNE 2010
X
CAD $5,000,000
Patient Home Monitoring Corp.
Equity Line
JUNE 2010
X
CAD $9,200,000
Resverlogix Corp.
Overnight Offering
JUNE 2010
X
CAD $4,500,000
Patient Home Monitoring Corp.
Private Placement
JUNE 2010
X
Patient Home Monitoring Corp.
MERGER & ACQUISITION ADVISORY
JUNE 2010
X
Approx. CAD $7,000,000
DiaMedica Inc.
MERGER & ACQUISITION ADVISORY
JUNE 2010
X
Cipher Pharmaceuticals Inc.
MONETIZATION PLANNING
JUNE 2010
X
Medicago Inc.
MONETIZATION PLANNING
JUNE 2010
X
CAD $10,000,000
Medicago Inc.
Equity Line
MAY 2010
X
US $17,500,000
YM Biosciences Inc.
Registered Direct Offering
MARCH 2010
X
Conjuchem LLC
MERGER & ACQUISITION ADVISORY
MARCH 2010
X
Approx. CAD $12,500,000
YM Biosciences Inc.
MERGER & ACQUISITION ADVISORY
FEBRUARY 2010
X
CAD $8,000,000
Resverlogix Corp.
Private Placement
JANUARY 2010
X
Medicure Inc.
MERGER & ACQUISITION ADVISORY
JANUARY 2010
X
CAD $25,000,000
LaboPharm Inc.
Equity Line
NOVEMBER 2009
X
CAD $11,592,000
Medicago Inc.
Bought Deal
NOVEMBER 2009
X
US $14,662,500
Oncolytics Biotech Inc.
Overnight Offering
NOVEMBER 2009
X
CAD $750,000
Patient Home Monitoring Corp.
Private Placement
OCTOBER 2009
X
CAD $1,500,000
Chemaphor Inc.
Private Placement
APRIL 2009
X
DRM Ventures Inc.
MERGER & ACQUISITION ADVISORY
OCTOBER 2009
X
CAD $500,000
Med BioGene Inc.
Private Placement
SEPTEMBER 2009
X
Bradmer Pharmaceuticals Inc.
MERGER & ACQUISITION ADVISORY
JULY 2009
X
CAD $58,700,000
Paladin Labs Inc.
Bought Deal
JUNE 2009
X
Med BioGene Inc.
MERGER & ACQUISITION ADVISORY
June 2009
X
CAD $380,000
Chemaphor Inc.
Private Placement
APRIL 2009
